Dispensation of attention deficit hyperactivity disorder (ADHD) medications in patients receiving opioid agonist therapy; a national prospective cohort study in Norway from 2015 to 2017

Dispensation of attention deficit hyperactivity disorder (ADHD) medications in patients receiving opioid agonist therapy; a national prospective cohort study in Norway from 2015 to 2017

Abstract Background It is estimated that up to a third of patients on opioid agonist therapy (OAT) have attention deficit hyperactivity disorder (ADHD). Treatment by ADHD medication, including a centrally acting stimulant (CAS) or atomoxetine is one of the essential approaches. This study evaluates...

Full description

Bibliographic Details
Main Authors: Jørn Henrik Vold, Christer Aas, Svetlana Skurtveit, Ingvild Odsbu, Fatemeh Chalabianloo, Anne Halmøy, Kjell Arne Johansson, Lars Thore Fadnes
Format: Article
Language:English
Published: BMC 2020-03-01
Series:BMC Psychiatry
Subjects:
Opioid substitution treatment
Centrally acting stimulants
Hyperkinetic disorder
Attention deficit hyperactivity disorder
Substance-related disorders
Dispensed drugs
Online Access:http://link.springer.com/article/10.1186/s12888-020-02526-y

Internet

http://link.springer.com/article/10.1186/s12888-020-02526-y

Similar Items